Cullinan Associates Inc. lowered its position in Sanofi SA (NYSE:SNY) by 5.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 76,500 shares of the company’s stock after selling 4,300 shares during the quarter. Cullinan Associates Inc.’s holdings in Sanofi were worth $3,321,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in SNY. BlackRock Inc. grew its position in Sanofi by 0.7% in the 2nd quarter. BlackRock Inc. now owns 3,328,180 shares of the company’s stock worth $133,161,000 after purchasing an additional 22,425 shares during the last quarter. First Republic Investment Management Inc. grew its position in Sanofi by 12.3% in the 2nd quarter. First Republic Investment Management Inc. now owns 115,412 shares of the company’s stock worth $4,618,000 after purchasing an additional 12,609 shares during the last quarter. Natixis bought a new position in Sanofi in the 2nd quarter worth about $213,000. Marshall Wace LLP bought a new position in Sanofi in the 2nd quarter worth about $1,685,000. Finally, Cozad Asset Management Inc. bought a new position in Sanofi in the 2nd quarter worth about $263,000. 7.04% of the stock is owned by institutional investors.

Several research analysts have commented on SNY shares. Guggenheim started coverage on shares of Sanofi in a research report on Monday, October 8th. They issued a “neutral” rating for the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Monday, October 15th. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “sell” rating in a research report on Tuesday, October 16th. ValuEngine upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Wednesday, October 17th. Finally, Wolfe Research began coverage on shares of Sanofi in a report on Tuesday, October 23rd. They issued a “market perform” rating for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $50.00.

Sanofi stock opened at $42.44 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $108.88 billion, a PE ratio of 13.56, a P/E/G ratio of 2.41 and a beta of 0.67. Sanofi SA has a 12-month low of $37.43 and a 12-month high of $45.86.

Sanofi (NYSE:SNY) last posted its quarterly earnings data on Wednesday, October 31st. The company reported $1.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.09. The business had revenue of $9.39 billion during the quarter, compared to analysts’ expectations of $9.10 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The business’s revenue was up 1.5% on a year-over-year basis. During the same period last year, the firm posted $1.71 earnings per share. As a group, sell-side analysts anticipate that Sanofi SA will post 3.1 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://theolympiareport.com/2019/01/12/cullinan-associates-inc-sells-4300-shares-of-sanofi-sa-sny.html.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: What is a put option?

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.